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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.012Transplantation of mesenchymal stem-like cells to the heart is known to improve cardiac recovery in
animal models of myocardial infarction (MI). Because stimulation of A2B adenosine receptors on mouse
cardiac stem cell antigen (Sca)-1þCD31 mesenchymal stem-like cells signiﬁcantly up-regulates their
secretion of pro-angiogenic factors, we hypothesized that ablation of the A2B receptor signaling in
these cells would reduce their ability to improve vascularization of the infarct area seen after trans-
plantation. Wild-type (WT) C57BL/6 mice underwent permanent left coronary artery ligation and
received intramyocardial injections of Sca-1þCD31 cells generated from WT or A2B receptor knockout
(A2BKO) mice or the same volume of cell-free saline. Only 12% to 16% of injected cells remained in the
ventricles 1 week later; there was no signiﬁcant difference between WT and A2BKO cell survival.
Transplantation of WT, but not A2BKO, cells signiﬁcantly reduced both post-MI decline in cardiac
function and adverse remodeling compared with that seen in control hearts. Morphological analysis
conducted 4 weeks after MI revealed signiﬁcantly increased vascularization of the infarct areas and
reduced myocardial scarring in animals treated with WT, but not with A2BKO, cells compared with
control. Thus, our study demonstrated that the A2B receptor signaling linked to up-regulation of pro-
angiogenic factors in cardiac Sca-1þCD31 stromal cells is essential for overall improvement of cardiac
recovery seen after their transplantation to the injured heart. (Am J Pathol 2013, 183: 665e672;
http://dx.doi.org/10.1016/j.ajpath.2013.05.012)Supported by NIH grants R01HL095787 and R01CA138923 (I.F.).Mesenchymal stem-like cells of various tissue origins have
been proposed to be used in cell-based transplantation
therapy to enhance tissue repair and functional recovery
after myocardial infarction (MI). Among them, cardiac
mesenchymal stem-like cells have been consistently shown
to possess superior paracrine potency and myocardial pro-
tection efﬁcacy compared with stem/progenitor cells origi-
nated from other tissues.1,2 In the mouse heart, these cells are
represented by a population of stromal cells characterized by
the expression of stem cell antigen (Sca)-1 on their surface and
the absence of the endothelial cell surface marker, CD31.3e9
Several groups independently reported that the delivery of
cardiac Sca-1þCD31 cell populations to the heart resulted in
improved revascularization of injured tissue and attenuated
decline of cardiac function in animal models of MI.6,9e11
Although the precise mechanism of these protective effectsstigative Pathology.
.remains unknown, the early assumption that these cells can
replace damaged cardiomyocytes has recently given way to
the realization that they also, and perhaps mainly, exert
a beneﬁcial effect via the release of paracrine factors.3,12e17
As such, the beneﬁcial properties of transplanted cells are
likely regulated by local factors present in the ischemic tissue,
including high levels of extracellular adenosine.
Adenosine is an endogenously produced signaling mole-
cule that binds to the family of extracellular G-proteine
coupled seven transmembrane receptors, which include A1,
A2A, A2B, and A3 subtypes. Adenosine concentrations in the
myocardial interstitium remain low in normal conditions.
Myocardial ischemia is known to considerably increase
extracellular adenosine levels.18,19 MI results in even larger
Ryzhov et allevels of extracellular adenosine because of its massive
release from damaged cells and catabolism of coreleased
adenine nucleotides. Subsequent inﬂammation in the injured
myocardium may further increase extracellular adenosine
levels as the result of cell stress and tissue hypoxia.20
Therefore, extracellular adenosine becomes an important
part of the tissue microenvironment generated by myocardial
ischemia and infarction.
Recently, we found that stimulation of A2B adenosine
receptors on mouse cardiac Sca-1þCD31 stromal cells
signiﬁcantly increased secretion of pro-angiogenic factors.21
In this study, we tested the hypothesis that the A2B receptor
signaling in these cells is important for their therapeutic
effects seen after transplantation to the heart after MI.
Materials and Methods
Mouse Cardiac Sca-1þCD31 Stromal Cells
Wild-type (WT) and A2B receptor knockout (A2BKO) con-
ditionally immortalized cardiac Sca-1þCD31 stromal cell
lines were generated, as described previously,21 from H-2Kb-
tsA58 transgenicmice carryinga thermolabileT antigen crossed
withWT andA2BKOmice, respectively. Cells were propagated
on 0.1% gelatin-coated tissue culture dishes in Dulbecco’s
modiﬁed Eagle’s medium (high glucose) (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum, 1 antibiotic-
antimycotic solution, 2 mmol/L glutamine (all from Sigma, St.
Louis, MO), and 10 ng/mL of interferon-g (R&D Systems,
Minneapolis, MN) under a humidiﬁed atmosphere of air/CO2
(19:1) at a low temperature (33C). Six days before experi-
ments, cells were replated and cultured in the absence of inter-
feron-g at a higher temperature (37C) to allow them to revert to
their primary phenotype, as described previously.21 Immedi-
ately before surgery, cells were harvested by treatment with
Accutase-EnzymeCell DetachmentMedium (eBioscience, San
Diego, CA), washed, and resuspended in PBS for trans-
plantation. In some experiments, cells were detached, incubated
at a concentration of 106 cells/mL in Dulbecco’s modiﬁed
Eagle’s medium in the presence of 1 mL/mL of Vybrant 1,10-
dioctadecyl-3,3,30,30-tetramethylindodicarbocyanine iodide
(DiD) cell-labeling solution (Life Technologies, Grand Island,
NY) for 20 minutes, washed, and replated 72 hours before
surgery. In parallel, a portion of harvested cellswas resuspended
in Dulbecco’s modiﬁed Eagle’s medium to analyze adenosine-
dependent vascular endothelial growth factor (VEGF) secretion.
Flow Cytometry
Cells were analyzed either freshly isolated from ventricles
or after culture, as described previously,21 using an LSRII
ﬂow cytometer (Becton Dickinson, Franklin Lakes, NJ).
Analysis of Adenosine-Dependent VEGF Secretion
Harvested Sca-1þCD31 cells were cultured in 6-well plates
overnight at 37C to allow cell attachment. Cells were666washed and incubated in a fresh medium in the presence or
absence of the stable adenosine analogue 50-N-ethylcarbox-
amidoadenosine (NECA; 10 mmol/L) and 1 U/mL adenosine
deaminase (both from Sigma). After collection of culture
media, the cells were detached and counted. VEGF concen-
trations in culture media were measured using enzyme-linked
immunosorbent assay kits (R&D Systems).
MI and Cell Transplantation
All studies were conducted in accordance with the Guide for
the Care and Use of Laboratory Animals, as adopted and
promulgated by the NIH (Bethesda, MD). Animal studies
were reviewed and approved by the Vanderbilt Institutional
Animal Care and Use Committee. Surgical procedures to
produce MI in mice were performed in the Cardiovascular
Pathophysiology and Complications Core of the Vanderbilt
University Mouse Metabolic Phenotyping Center, as previ-
ously described.22 Male 10- to 12-week-old WT C57BL/6
mice (Harlan World Headquarters, Indianapolis, IN) were
used in all experiments. MI was produced by permanent
ligation of the left coronary artery. A total of 2.5 105WT or
A2BKO cardiac Sca-1
þCD31 stromal cells, suspended in 25
mL of PBS, were injected into the peri-infarct area. Equal
volumes of cell-free PBS were injected in the same manner to
a control group of animals.
Echocardiography
Echocardiography was performed on unsedated mice using
a Vevo 2100 Imaging System equipped with an 18- to
38-MHz linear-array transducer (MS400; VisualSonics, Inc.,
Toronto, ON, Canada). Images were acquired at the rate of
300 frames per second. Left ventricular M-mode tracings
were obtained at the level of papillary muscles using the
two-dimensional parasternal short axis imaging as a guide.
All image acquisitions, left ventricular measurements, and
calculations of functional parameters were conducted in the
Cardiovascular Pathophysiology and Complications Core of
the Vanderbilt University Mouse Metabolic Phenotyping
Center by an experienced echocardiographer who was blin-
ded to animal groups.
Determination of Scar Size
To measure infarct size, excised hearts were immersion
ﬁxed in 10% buffered formalin for 24 hours and transferred
to 70% ethanol, after which ventricles were cut into three
equal parts (in length) parallel to the atrioventricular groove.
From each parafﬁn-embedded ventricular part, two trans-
verse sections (5 mm thick) were made at different levels
(for a total of six sections). After performing Masson-
trichrome staining, infarct sizes were determined by the
midline length measurement method.23 All measurements
were conducted using ImageJsoftware version 1.45s (NIH)
in a blinded manner.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Characterization of WT and A2BKO Sca-1þCD31 cells before transplantation. A: Representative cytoﬂuorographic outlier contour plots of
tsA58Tag expression determined with monoclonal Pab108 antibody (Pab108) in WT and A2BKO Sca-1
þCD31 cells cultured under permissive (left panels) and
nonpermissive (right panels) conditions. Isotype-matching antibody (Isotype) was used as a negative control. B: Graphic representation of data from ﬂow
cytometry analysis of intracellular tsA58Tag staining of WT and A2BKO Sca-1
þCD31 cells cultured under permissive (closed bars) and nonpermissive conditions
(open bars). Values are means  SEM of three experiments. C: Flow cytometry histograms of WT (blue) and A2BKO (red) Sca-1þCD31 cells labeled with DiD.
Shaded areas represent the ﬂuorescence of unlabeled cells. D: Graphic representation of data from ﬂow cytometry analysis of DiD labeling of WT and A2BKO
Sca-1þCD31 cells. Values are means  SEM of ﬁve experiments. MFI, mean ﬂuorescence intensity. E: Up-regulation of VEGF release after stimulation of
adenosine receptors in WT, but not A2BKO, Sca-1
þCD31 cells. WT or A2BKO cells were incubated in the absence (basal) or presence of 10 mmol/L NECA
(þNECA) for the indicated times, and VEGF was measured in supernatants. Values are means  SEM of three experiments. Asterisks indicate statistical
difference compared with corresponding basal levels: **P < 0.01, ***P < 0.001, unpaired two-tailed t-test.
Adenosine and CardioprotectionDetermination of Vascular Density in the Infarct Area
Parafﬁn sections at the midventricular level, adjacent to
those used for Masson-trichrome staining, were processed
for immunoperoxidase staining of endothelial cells using
rabbit anti-mouse von Willebrand factor (Sigma) as a
primary antibody to visualize blood vessels, as previously
described.24 One medium-power (10 magniﬁcation) ﬁeld
in the central and two 10 ﬁelds in the marginal areas of the
scar from each slide were selected, and digitized images of
these ﬁelds (0.88  0.67 mm) were used to count all stained
vascular structures in a blinded manner. The tissue area was
measured in each ﬁeld, and vascular density was expressed
as number of blood vessels per mm2 of tissue.Statistical Analysis
Data were analyzed using GraphPad Prism software version
4.0 (GraphPad Software Inc., San Diego) and presented as
means  SEM. Comparisons between several treatment
groups were performed using one-way analysis of variance,
followed by appropriate posttests. Comparisons betweenThe American Journal of Pathology - ajp.amjpathol.orgtwo groups were performed using two-tailed unpaired
t-tests. P < 0.05 was considered signiﬁcant.
Results
Sca-1þCD31 cells used in this study carry a gene encoding
the thermolabile T antigen (tsA58Tag), which can be detec-
ted by ﬂow cytometry after staining with the monoclonal
antibody Pab108 (Pharmingen, San Diego). Figure 1, A and
B, shows that >80% of cells under permissive conditions
(33C with interferon-g) are stained with Pab108, whereas
<8% of cells can be stained with Pab108 after 48 hours of
culture at a higher temperature of 37C. No difference in
Pab108 staining was seen between WT and A2BKO cells
(Figure 1B). Therefore, we used the temperature-dependent
Pab108 staining to trace the fate of injected cells in further
experiments. In addition, cells were labeled with the lipo-
philic cell tracer, DiD. Figure 1, C and D, demonstrates
identical levels of DiD ﬂuorescence in labeled WT and
A2BKO cells before their injection. To ensure that coupling of
adenosine A2B receptors to paracrine functions is preserved
in cells prepared for transplantation experiments, we tested667
Figure 2 A2B receptor signaling in Sca-1þCD31 stromal cells has no effect on their survival 1 week after transplantation but results in more endothelial
cells in the infarcted hearts. A: Representative cytoﬂuorographic outlier contour plots of CD31 and CD45 expression and Sca-1þDiDþ cells presented as
percentage of CD31CD45 cells in single-cell suspensions obtained from ventricles injected with WT or A2BKO Sca-1
þCD31 cells labeled with DiD, or cell-free
PBS control. B: Total numbers of DiD-labeled WT and A2BKO Sca-1
þCD31 cells calculated from data shown in A and total numbers of CD31CD45 cells in each
ventricular single-cell suspension. Values are means  SEM of nine animals in each group. C: Total numbers of CD31þCD45 endothelial cells calculated from
data shown in A and total numbers of cells in each ventricular single-cell suspension. Values are means  SEM of nine animals in each group. Asterisks
indicate signiﬁcant difference compared with cell-free control: **P < 0.01, one-way analysis of variance with Dunnett’s posttest. D: Representative cyto-
ﬂuorographic outlier contour plots of tsA58Tag expression determined with monoclonal Pab108 antibody (Pab108) in single-cell suspensions obtained from
ventricles injected with WT or A2BKO Sca-1
þCD31 cells and cultured under nonpermissive (left panels) and permissive (right panels) conditions for 48 hours.
Isotype-matching antibody (Isotype) was used as a negative control. E: Total numbers of WT and A2BKO Sca-1
þ cells expressing tsA58Tag under nonpermissive
(open bars) and permissive (closed bars) conditions calculated from data shown in D and total numbers of cells in each ventricular single-cell suspension.
Values are means  SEM of ﬁve animals in each group.
Ryzhov et altheir response to the stable adenosine analogue, NECA, using
VEGF release as a marker. Indeed, onlyWT, but not A2BKO,
Sca-1þCD31 cells responded to stimulation with 10 mmol/L
NECA by a signiﬁcant increase in VEGF release (Figure 1E).
To assess the role of A2B receptors in the protective effects
of Sca-1þCD31 cells after MI, three groups of WT mice
underwent permanent ligation of the left coronary artery and
WT or A2BKO cells (2.5 105 in 25 mL of PBS), or the same
volume of PBS without suspended cells was directly injected
into the left ventricular myocardium. In an ancillary study,
survival of injected cells was evaluated by ﬂow cytometry 1
week after surgery. In myocyte-free single-cell suspensions
isolated from ventricles injected with WT or A2BKO
Sca-1þCD31 cells, DiDþ cells were found only within the
CD31CD45 cell population. DiDþ cells also retained their
Sca-1 expression (Figure 2A). Approximately 12% of injected668DiD-labeled cells still remained in the ventricles; no difference
in DiDþ cell numbers was found between hearts injected with
WT and A2BKO cells (Figure 2B). Of interest, we found
signiﬁcantly more endothelial (CD31þCD45) cells in
ventricles of hearts injected with WT, but not A2BKO, cells
compared with control (Figure 2C). In a complementary
approach, we evaluated survival of injected cells by their
expression of tsA58Tag induced by incubation under permis-
sive conditions for 24 hours (Figure 2D). Only 4  0.4  104
cells in individual ventricle single-cell preparations, corre-
sponding to approximately 16% of injected Sca-1þCD31
cells, were stained with Pab108 under permissive conditions;
no difference in Pab108þ cell numbers was found between
hearts injected with WT and A2BKO cells (Figure 2E).
Postinfarction changes in cardiac function in all experi-
mental groups were assessed in a blinded manner usingajp.amjpathol.org - The American Journal of Pathology
Figure 3 Transplantation of WT, but not
A2BKO, Sca-1
þCD31 cells signiﬁcantly attenuated
the deterioration of cardiac function after MI. A:
Timeline of the study protocol. LCA, left coronary
artery. B: Representative echocardiograms recor-
ded 4 weeks after transplantations of WT or A2BKO
Sca-1þCD31 cells, or vehicle control (PBS). C: LV
fractional shortening was signiﬁcantly improved 1
and 4 weeks after WT, but not A2BKO Sca-1
þCD31,
cell transplantation compared with cell vehicle
control (PBS). D: End-diastolic left ventricular
internal diameter (LVIDd) was signiﬁcantly smaller
4 weeks after WT, but not A2BKO, Sca-1
þCD31 cell
transplantation compared with cell vehicle control
(PBS). E: End-systolic left ventricular internal
diameter (LVIDs) was signiﬁcantly smaller 4 weeks
after WT, but not A2BKO, Sca-1
þCD31 cell trans-
plantation compared with cell vehicle control
(PBS). F: LV ejection fraction was signiﬁcantly
improved 4 weeks after WT, but not A2BKO, Sca-
1þCD31 cell transplantation compared with cell
vehicle control (PBS). Values are expressed as
means  SEM (n Z 6 to 7 animals per group).
Asterisks indicate signiﬁcant difference compared
with controls (PBS): *P < 0.05, one-way analysis
of variance with Dunnett’s posttest.
Adenosine and Cardioprotectionechocardiography (Figure 3, A and B). Changes in the left
ventricular fractional shortening values (Figure 3C) were
calculated from left ventricular internal dimension (LVID)
end-diastolic (Figure 3D) and end-systolic (Figure 3E)
measurements taken before and 1 and 4 weeks after MI. In
agreement with previous reports on protective properties
of cardiac Sca-1þCD31 cells,6,9e11 we found that trans-
plantation of WT cells signiﬁcantly reduced a decrease in
fractional shortening observed 1 and 4 weeks after MI
compared with PBS control. In contrast, transplantation of
A2BKO cells had no effect on the postinfarction decline in
cardiac function seen in the control group (Figure 3C).
Similar effects of cell transplantation on cardiac function
were found by analysis of left ventricular ejection fraction
(Figure 3F). Transplantation of WT, but not A2BKO, cells
also ameliorated adverse changes in LVID measurements,
with signiﬁcantly reduced end-diastolic (Figure 3D) and
end-systolic (Figure 3E) LVID on postinfarction week 4
compared with that seen in PBS-treated control hearts.
In agreement with echocardiographic data, morpholog-
ical analysis conducted 4 weeks after MI revealed signif-
icantly reduced myocardial scarring in the animals treated
with WT cells compared with the control animal group. In
contrast, there was even a tendency for an increase in scar
size in the A2BKO cell-treated group, albeit not statistically
signiﬁcant, when compared with the control PBS-treated
group (Figure 4, A and C).
Finally, we examined if the lack of A2B receptoremediated
pro-angiogenic signaling in the transplanted cardiacThe American Journal of Pathology - ajp.amjpathol.orgSca-1þCD31 stromal cells would translate into reduced
stimulation of revascularization of the infarcted area.
Figure 4B shows representative micrographs (4 magniﬁ-
cation) of Masson-trichromeestained infarcted areas, with
boxed areas corresponding to the ﬁelds (10 magniﬁcation)
where all vascular structures identiﬁed by von Willebrand
factor immunostaining were systematically counted. Magni-
ﬁed images (40 magniﬁcation) of immunostained blood
vessels are also presented in Figure 4B. In agreement with
previous reports,6,9e11 we found that transplantation of WT
Sca-1þCD31 cells signiﬁcantly increased vascularization of
the infarcted areas compared with that seen in the control
PBS-treated hearts. In contrast, the vascular density in the
infarcted areas of hearts injected with A2BKO cells was no
different from that seen in the control PBS-treated group
(Figure 4D). Taken together, our data suggest that A2B
receptoredependent regulation of pro-angiogenic properties
of cardiac Sca-1þCD31 stromal cells may play an important
role in neovascularization and cardioprotection after MI.Discussion
Tissue damage and inﬂammatory reactions after MI trigger
release and generation of adenosine, which accumulates at
high levels in the extracellular compartment. There is
growing evidence that adenosine can modulate multiple
facets of myocardial injury and remodeling via binding to
the low-afﬁnity A2B adenosine receptor subtype. Adenosine669
Figure 4 Transplantation of WT, but not A2BKO, Sca-1þCD31 cells
signiﬁcantly reduced infarct scar size and increased vascular density in the
infarct area. A: Representative Masson-trichromeestained heart sections 4
weeks after transplantations of WT or A2BKO Sca-1
þCD31 cells, or vehicle
control (PBS). B: Representative micrographs of infarcted areas stained
with Masson-trichrome (top panels) or immunostained for von Willebrand
factor (brown staining in the middle and bottom panels) 4 weeks after
transplantations of WT or A2BKO Sca-1
þCD31 cells, or vehicle control
(PBS). Boxed areas indicate regions of magniﬁcation. Scale barZ 200 mm
(middle panels). C: Infarct scar size calculated as percentage of the total
midline circumference averaged from six sections per heart. See Materials
and Methods for details. Values are expressed as means  SEM (n Z 6 to
7 animals per group). D: Vascular density calculated as a number of blood
vessels per mm2 of scar tissue. Entire areas of middle-power ﬁelds (middle
panels) in B were systematically analyzed. Original magniﬁcation, 10.
See Materials and Methods for details. Values are expressed as means  SEM
(n Z 6 to 7 animals per group). Asterisks indicate signiﬁcant difference
compared with control (PBS): *P < 0.05, **P < 0.01, one-way analysis of
variance with Dunnett’s posttest.
Ryzhov et alA2B receptors have been shown to promote neovasculari-
zation in tumors,25 lung,26 retina,27 and skeletal muscles24
by promoting the release of pro-angiogenic factors. We
have recently reported that A2B receptors are essential for
adenosine-dependent up-regulation of paracrine functions of
cardiac Sca-1þCD31 stromal cells, which can serve as an
important source of pro-angiogenic stimuli in the heart.21670Herein, we explored the relevance of our ﬁndings to
previously described therapeutic properties of these cells,
which reportedly increased neovascularization of the infarct
scar area when injected intramyocardially in a mouse model
of MI.6,10,11 We found that injected A2BKO Sca-1
þCD31
cells failed to reproduce the pro-angiogenic effects of WT
cells, which, in agreement with previous reports,6,10,11 in-
duced a signiﬁcant increase in vascularization of infarcted
hearts. Furthermore, we found that transplantation ofWT, but
not A2BKO, Sca-1
þCD31 cells into the infarcted hearts
resulted in increased endothelial cell numbers already
detectable 1 week later. This increase could not be explained
by preferential differentiation of injected WT Sca-1þCD31
cells to endothelial cells because the cell tracer, DiD, was not
found in the endothelial cell population 1 week after injection
of DiD-labeled cells. Results of cell fate tracing experiments
using DiD and the expression of tsA58Tag suggest that only
12% to 16% of injected cells remain in the infarcted heart at
this time point, but no differences in their survival or
phenotype were found between WT and A2BKO cells.
In parallel experiments, we veriﬁed that WT and A2BKO
cells used for transplantation differed only in adenosine-
dependent, but not basal, secretion of VEGF, a potent pro-
angiogenic factor. However, VEGF secretion is not the only
function that can be affected by the loss of A2B receptors in
transplanted cells. Cardiac Sca-1þCD31 stromal cells
represent a rich source of paracrine factors. We have previ-
ously shown that stimulation of A2B receptors on these cells
also up-regulates production of CXCL-1 and IL-6,21 factors
implicated in the regulation of neovascularization.28,29 It is
possible, therefore, that the cumulative effect of several
paracrine factors up-regulated by A2B receptors can con-
tribute to the observed difference between WT and A2BKO
cells in their ability to stimulate neovascularization.Our study
also demonstrated that transplanted Sca-1þCD31 stromal
cells decreased scar size and improved cardiac function after
MI only when A2B receptor signaling was preserved in these
cells. It is likely that the loss of pro-angiogenic factors
contributes to the loss of cardioprotection when A2BKO cells
are used, given that the development of neovascularization
within the infarcted area is an integral part of cardiac repair,
leading to long-term salvage and survival of viable myocar-
dium, reduction in collagen deposition, and improvement in
cardiac function.
We cannot exclude, however, that other potential mech-
anisms of therapeutic cell actions may be affected by the
loss of A2B receptors. In addition to their well-recognized
pro-angiogenic effects, paracrine factors released by
cardiac Sca-1þCD31 stromal cells have been implicated in
stimulation of receptor-mediated survival pathways.3,9
Sca-1þCD31 stromal cells have been also suggested to
play a role of resident progenitor cells in the heart because
they can be induced in vitro to transdifferentiate under
appropriate conditions into different cell lineages, including
cardiomyocytes.4e6,8,10,30,31 However, the number of re-
ported cardiomyocytes derived from Sca-1þCD31 cellsajp.amjpathol.org - The American Journal of Pathology
Adenosine and Cardioprotectionwas reportedly too low to account for the signiﬁcant
enhancement of cardiac function in this in vivo model.6
Furthermore, we have previously demonstrated that stimu-
lation of A2B receptors on cardiac Sca-1
þCD31 stromal
cells has no effect on their cardiomyogenic differentiation
in vitro.21 Therefore, it is unlikely that potential changes in
differentiation of Sca-1þCD31 cells into cardiomyocytes
can contribute signiﬁcantly to the observed difference
between the effects of WT and A2BKO cell injections on
postinfarction cardiac function.
Systemic pharmacological modulation of A2B receptor
signaling has been recently used to analyze the role of these
receptors in MI. Paradoxically, inhibition of A2B receptors
with the selective antagonist, GS-6201, early after coronary
artery ligation resulted in improved cardiac function com-
pared with vehicle controls.32 On the other hand, stimula-
tion of A2B receptors starting a week after coronary artery
ligation also improved cardiac function compared with
vehicle controls.33 These seemingly contradictory reports
may be attributed to potential adverse effects of A2B
receptor signaling in cells active during the initial phase of
MI (eg, inﬂammatory cells) and beneﬁcial effects of these
receptors in other cell types active during the healing phase,
which occurs later. In the current study, we took advantage
of a previously established model of Sca-1þCD31 cell
transplantation into the infarcted heart to improve cardiac
recovery. In contrast to systemic inhibition of A2B receptors,
we abrogated A2B receptor signaling only in transplanted
cardiac Sca-1þCD31 stromal cells to analyze its role
speciﬁcally in these cells, thus bypassing the potential
effects of blocking A2B receptor signaling in other cell types
during the acute inﬂammation phase of MI. In agreement
with the observed beneﬁcial effects of A2B receptor stimu-
lation during the healing phase of MI, our study suggests
that stimulation of A2B receptors on resident Sca-1
þCD31
stromal cells may lead to an increase in neovascularization
of infarcted hearts and contribute to the overall car-
dioprotection after MI. In this study, we used a previously
described and well-reproducible experimental design with
injection of the cells immediately after MI induction.6,9e11
The use of mesenchymal stem-like cells in the clinic
would require a considerably longer period between onset of
MI and therapeutic cell injections. Considering the reported
beneﬁts of pharmacological inhibition of A2B receptors
early after MI,32 it would be interesting to explore potential
added beneﬁts of Sca-1þCD31 injections shortly after
completion of initial treatment with A2B receptor antago-
nists. Also, because MI-induced interstitial adenosine levels
may be already on decline by that time, it would be
important to determine whether up-regulation of the A2B
receptor signaling before cell transplantation could boost
their therapeutic effects. This could be accomplished by
exposing the cells to hypoxia ex vivo, as we demonstrated
previously in different cell types.34
In conclusion, our study provided new in vivo evidence
for a pro-angiogenic role of A2B receptors on cardiacThe American Journal of Pathology - ajp.amjpathol.orgSca-1þCD31 stromal cells. For the ﬁrst time, to our
knowledge, we demonstrated that the A2B adenosine re-
ceptor signaling linked to up-regulation of pro-angiogenic
factors in Sca-1þCD31 cells is essential for overall car-
dioprotective properties of these cells in a mouse model of
MI. We have recently demonstrated that the human heart
harbors a population of mesenchymal stem-like cells similar
to the mouse cardiac Sca-1þCD31 stromal cells that
increase release of pro-angiogenic factors in response to A2B
receptor stimulation.21 Therefore, it is likely that our current
ﬁndings in mice can be translated to humans.
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